Get the Stockscreener App
11.93
3.17%
0.42
Corbus Pharmaceuticals Holdings Inc stock is traded at $11.93, with a volume of 423.70K.
It is up +3.17% in the last 24 hours and up +13.31% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$11.51
Open:
$11.46
24h Volume:
423.70K
Relative Volume:
1.62
Market Cap:
$221.59M
Revenue:
$1.54M
Net Income/Loss:
$-78.54M
P/E Ratio:
-1.9957
EPS:
-5.978
Net Cash Flow:
$-64.50M
1W Performance:
+7.66%
1M Performance:
+13.31%
6M Performance:
-1.12%
1Y Performance:
+57.49%
1-Day Range:
$11.26
$12.88
1-Week Range:
$9.09
$12.88
52-Week Range:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
11.96 | 213.25M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
435.83 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.53 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.07 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.91 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.22 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
CRBP Maintained by Mizuho -- Price Target Raised to $44.00 - GuruFocus
Mizuho raises Corbus Pharmaceuticals stock price target on ASCO preview By Investing.com - Investing.com Canada
Colliers facilitates 36,471 s/f lease renewal for Corbus Pharmaceuticals - NEREJ
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout - inkl
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxen - The National Law Review
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (CRBP) grants RSUs and stock options to director - Stock Titan
Corbus Pharmaceuticals (CRBP) director granted RSUs and 12,300 stock options - Stock Titan
Corbus Pharmaceuticals (CRBP) director receives RSUs and 12,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) director Anne Altmeyer receives RSU and stock option grants - Stock Titan
Equity grants increase Corbus (CRBP) director Ben Yong’s holdings - Stock Titan
Corbus (NASDAQ: CRBP) director receives RSU and stock option grants in equity package - Stock Titan
Corbus Pharmaceuticals (CRBP) director Brent Pfeiffenberger files initial Form 3 - Stock Titan
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Announces Pre-ASCO 2026 Data for CRB-701 in Oncology Trials - Minichart
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - markets.businessinsider.com
Corbus Pharmaceuticals Appoints First Chief Business Officer - TipRanks
Corbus Pharmaceuticals announces the appointment of Nishant Saxena as chief business officer - marketscreener.com
Corbus appoints Brent Pfeiffenberger to board with equity awards - TradingView
Corbus Pharmaceuticals Holdings, Inc. announced that it will initiate a registration study of CRB-701 in second-line treatment for head and neck squamous cell carcinoma this summer. - Bitget
Corbus (NASDAQ: CRBP) hires Nishant Saxena as CBO, plans CRB-701 data call - Stock Titan
Corbus Pharmaceuticals Announces the Appointment of Nishant - GlobeNewswire
We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Understanding Momentum Shifts in (CRBP) - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors - Moomoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Octagon/Dr. Jia report 0 shares in Corbus (CRBP) — Schedule 13G/A - Stock Titan
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board - Investing.com UK
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board By Investing.com - Investing.com Nigeria
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Board, Advances CRB-701 and CRB-913 Clinical Programs - Minichart
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates - TipRanks
Corbus Pharmaceuticals appoints pharma industry veteran Brent Pfeiffenberger to board of directors - marketscreener.com
Cor appoints Brent Pfeiffenberger to board as independent director - TradingView
Corbus Pharmaceuticals (NASDAQ: CRBP) adds industry veteran to board and expands 2024 equity plan - Stock Titan
HC Wainwright Issues Positive Forecast for CRBP Earnings - MarketBeat
Brokers Offer Predictions for CRBP Q2 Earnings - MarketBeat
CRBP Maintained by Jefferies -- Price Target Lowered to $33.00 - GuruFocus
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $51 - Moomoo
Corbus Pharmaceuticals Holdings, Inc. schedules corporate overview at RBC and Jefferies healthcare events - Traders Union
CRBP Maintained by Oppenheimer -- Price Target Lowered to $54.00 - GuruFocus
CRBP Reiterates by Guggenheim -- Price Target Maintained at $45 - GuruFocus
CRBP: All proposals passed, including annual advisory votes on executive compensation - TradingView
CRBP: All five proposals, including director elections and equity plan amendment, were approved by majority - TradingView
Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating - marketscreener.com
Corbus Pharmaceuticals Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - ChartMill
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.06%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):